| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | MER, RP38, c-mer |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human MERTK |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MERTK抗体的3篇代表性文献示例(注：文献名称及作者为虚构，内容基于领域内常见研究方向概括)：
---
1. **文献名称**：*Targeting MERTK in Cancer with Blocking Antibodies Enhances Anti-Tumor Immunity*
**作者**：Smith A, et al.
**摘要**：该研究开发了一种靶向MERTK的单克隆抗体，通过阻断MERTK介导的免疫抑制信号，增强T细胞和巨噬细胞的抗肿瘤活性。在黑色素瘤和小鼠结肠癌模型中，抗体治疗显著抑制肿瘤生长，并与PD-1抑制剂表现出协同作用。
2. **文献名称**：*Structural Basis of MERTK Inhibition by Therapeutic Antibodies for Autoimmune Disease*
**作者**：Chen L, et al.
**摘要**：通过解析MERTK胞外域与治疗性抗体的复合物晶体结构，揭示了抗体特异性结合表位及抑制MERTK激活的分子机制。该抗体在类风湿性关节炎模型中有效减轻炎症反应，提示其治疗自身免疫疾病的潜力。
3. **文献名称**：*MERTK Antibody-Drug Conjugates for Targeted Therapy in Hematologic Malignancies*
**作者**：Johnson R, et al.
**摘要**：研究构建了MERTK抗体-药物偶联物(ADC)，在白血病和淋巴瘤模型中显示高效靶向杀伤效果，同时减少对正常细胞的毒性。该策略为MERTK高表达的血液肿瘤提供了新治疗方向。
---
**备注**：以上内容为领域内典型研究方向概括，实际文献需通过PubMed、Web of Science等平台检索关键词“MERTK antibody”或“MERTK therapeutic”获取具体信息。
MERTK (MER proto-oncogene tyrosine kinase) is a receptor tyrosine kinase belonging to the TAM family (TYRO3. AXL, MERTK), which regulates critical cellular processes including proliferation, survival, phagocytosis, and immune modulation. It is activated by ligands such as GAS6 and PROS1. initiating downstream signaling pathways like PI3K/AKT and MAPK. MERTK is notably overexpressed in various cancers (e.g., leukemia, glioblastoma, melanoma) and contributes to tumor progression, metastasis, and therapy resistance by enhancing pro-survival signals and suppressing anti-tumor immunity. In the tumor microenvironment, MERTK promotes immunosuppression by modulating macrophages and dendritic cells, limiting T-cell activation.
MERTK-targeting antibodies have emerged as promising therapeutic agents to block these oncogenic pathways. Preclinical studies demonstrate that anti-MERTK monoclonal antibodies (e.g., merestinib, sitravatinib) inhibit tumor growth, enhance phagocytosis of cancer cells, and synergize with checkpoint inhibitors. Clinical trials are exploring their efficacy in solid tumors and hematologic malignancies. Challenges include optimizing selectivity to avoid off-target effects on other TAM receptors, managing potential resistance mechanisms, and identifying predictive biomarkers. Beyond oncology, MERTK antibodies are investigated in autoimmune and inflammatory diseases due to their immunoregulatory roles. Their dual role in cancer and immunity highlights MERTK as a multifaceted therapeutic target.
×
